British regulators have sanctioned clinical trials for a new Ebola vaccine following an accelerated eight-week development period by University of Oxford scientists. This initiative follows the declaration of a public health emergency on May 17.
As the first of four experimental vaccines to reach this stage, researchers are currently recruiting 50 healthy volunteers aged 18 to 55 for initial testing. The study, led by Dr. Katrina Pollock, aims to confirm the vaccine’s ability to stimulate an immune response. Participants will be monitored for a full year.
The vaccine utilizes technology similar to the Oxford/AstraZeneca Covid vaccine. By modifying a common chimpanzee cold virus, researchers deliver genetic material from the Bundibugyo strain of Ebola to trigger the body’s defense mechanisms. This specific strain is responsible for the ongoing outbreak in the Democratic Republic of the Congo, which has already claimed hundreds of lives.
The Serum Institute of India has already manufactured approximately 620,000 doses, and parallel testing protocols ensure that speed does not compromise safety. While experts acknowledge potential, rare side effects similar to those associated with previous adenovirus-based vaccines, they emphasize that the risks of the Ebola virus itself are significantly higher.
